NCT00139152View on ClinicalTrials.gov

Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair

PHASE4CompletedINTERVENTIONAL

Enrollment

65

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Lung Disease

Interventions

DRUG

Placebo

Saline, Sub-Cuteanous (SQ)

DRUG

Xolair

Xolair, 0.016 mg/kg Immunoglobulions E (IgE) , SQ

Trial Locations (2)

12208

Albany Medical College, Albany

68131

Creighton University Division of Allergy & Immunology, Omaha

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Creighton University

OTHER